Quick answer
A patient-facing metric dividing total medication cost by total weight lost. Used to compare GLP-1 economics across drugs, doses, and pricing channels.
Full definition
Cost per pound (lost) is a back-of-envelope economic comparison metric calculated as total medication and program cost divided by total weight loss in pounds. At full retail (no insurance, no manufacturer savings), Wegovy at roughly $1,350/month and 14.9% TBWL gives a cost per pound of about $250-400 depending on starting weight. Tirzepatide tends to score better per pound due to greater efficacy. Compounded versions can be substantially cheaper per pound but carry quality and regulatory uncertainty. The metric does not capture quality of life, comorbidity reduction, or long-term value.
Deep dive
Cost Per Pound Lost: complete reference
Cost-per-pound is a comparative metric calculating total medication cost divided by pounds of weight lost — used to compare efficacy/value across weight-loss treatments. Calculation: (monthly cost × months of treatment) / pounds lost. Sample 2026 figures for 12-month treatment с trial-averaged weight loss: Wegovy at $1,349/month list = $16,188/year, with 14.9% loss from 220 lb baseline (~33 lb loss) = ~$490/lb; Zepbound list = ~$1,086/month × 12 = $13,032, с 22.5% loss (~49.5 lb) = ~$263/lb; Compounded semaglutide at $200/month × 12 = $2,400 с 14% loss (~31 lb) = ~$77/lb. LillyDirect Zepbound at $499/month for 22.5% loss = ~$121/lb. The metric oversimplifies — doesn't capture comorbidity benefits, CVD risk reduction, or long-term maintenance — but useful для initial cost comparison. Often referenced when patients compare bariatric surgery (~$15-25K one-time, 30% loss = $50-83/lb amortized over 5+ years) vs medication.
- In practice
- Wegovy at list price: ~$490 per pound lost over 1 year. Compounded semaglutide: ~$77 per pound. LillyDirect Zepbound: ~$121 per pound. These are simplified metrics ignoring health benefits.
- Clinical context
- Cost-per-pound is helpful comparison metric but doesn't capture full value (CVD benefit, comorbidity improvement, durable lifestyle change).
Medications
Cost Per Pound Lost is most directly relevant to the following GLP-1 medications:
Related terms
- Manufacturer Savings Card — A coupon or copay card provided by drug manufacturers to reduce out-of-pocket cost for commercially …
- LillyDirect — Eli Lilly's direct-to-patient pharmacy and telehealth platform launched in 2024, offering cash-pay Z…
- NovoCare — Novo Nordisk's patient support program that includes savings cards, copay assistance, and direct-pay…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)